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Context: Somatic or germline mutations in up to 15 disease-causative genes are detectable in up
to 50% of patients with pheochromocytoma (PCC) and paraganglioma (PGL). Very recently, so-
maticH-RASmutationswere identifiedbyexomesequencing inapproximately 7%in sporadic PCCs
and PGLs, in association with male sex and benign behavior.
Objective: To explore the prevalence of RAS mutations in a cohort of 271 PCC and PGL from a
European registry and to compare the genotype with clinical and pathological characteristics of
potential clinical interest.
Setting and Design: Genetic screening for hotspot mutations in H-, N-, and K-RAS genes was
performed by means of Sanger sequencing or pyrosequencing methods on tumor DNA in a series
of patients with (n  107) or without (n  164) germline or somatic PCC/PGL-related gene
mutations.
Results: Overall, H-RAS mutations were detected in 5.2% of cases (14/271), which were confined
to sporadic PCCs resulting in a prevalence of 10% (14/140) in this cohort. In contrast, nomutations
were found in PCC with PCC/PGL-related gene mutations (0/76) or in PGL (0/55) harboring or not
mutations in PCC/PGL susceptibility genes. In this large series, H-RASmutations in PCCs lacked any
significant correlation with pathological or basic clinical endpoints.
Conclusions: Somatic H-RAS mutations are restricted to a relevant proportion of sporadic PCC.
These findings provide the basis to study potential H-RAS-dependent correlations with long-term
outcome data. (J Clin Endocrinol Metab 99: E1376–E1380, 2014)
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Pheochromocytoma (PCC) and paraganglioma (PGL)are neural crest-derived tumors, arising from chro-
maffin cells of the adrenal medulla or from extra-adrenal
paraganglia (1). Approximately 50% of all PCC/PGL pa-
tients harbormutations, either somatic or germline, in one
of the 15 disease-causative genes: SDHA, SDHB, SDHC,
SDHD, SDHAF2, RET, VHL, NF1, MAX, TMEM127,
HIF2A, FH, KIF1B, PHD2, and IDH (2–9). Despite this
genetic heterogeneity, the tumors can be divided into two
groups based on transcription profiling studies. Cluster 1
includes tumors with mutations in VHL, HIF2A, and
SDHx (SDHA, SDHB, SDHC, SDHD, and SDHAF2)
and displays a pseudohypoxic signature; cluster 2 repre-
sents tumors with mutations in RET, NF1, TMEM127,
and MAX and displays an activation of kinase-signaling
pathways (PI3K/AKT/mTOR and RAS/RAF/ERK). Spo-
radic PCC and PGL can cluster within both groups (8,
10–12).
Recently, somaticH-RASmutations in sporadic PCCs
and PGLs were identified by exome sequencing, showing
a frequency of 6.9% (13), following a previous report by
Yoshimoto and coworkers (14). These tumors displayed
activation of the RAS/RAF/ERK-signaling pathway and
were associated with male predominance and clinically
benign behavior.
RAS is a family of relatedproteins consisting ofH-RAS,
K-RAS, andN-RAS, which are small GTPases involved in
cell growth, proliferation, and survival.RAS genes belong
to the most commonmutated genes in human cancer with
oncogenic mutation hotspots found in codons 12, 13, and
61. Whereas RAS GTPase signaling is self limiting due to
its intrinsic ability to exchange GTP with GDP-mutant
RAS protein is defective for this GTP hydrolysis and re-
mains constitutively active (15). RAS signaling activates
the RAF/ERK and PI3K/AKT/mTOR signaling pathways,
similar to what has been described in cluster 2
PCCs/PGLs(16).
In the present multi-institutional study, we aimed to
establish the prevalence ofH-RASmutation in a cohort of
PCCs and PGLs already genotyped for themain PCC/PGL
susceptibility genes, and correlated the presence of muta-
tions with major clinical and pathological parameters.
Materials and Methods
Patients selection and characteristics
A series of 271 samples was collected from different institu-
tions participating in the European Network for the Study of
Adrenal Tumors (ENS@T), www.ensat.org), and included 97
cases fromItaly, 39 cases fromSpain, 126 fromTheNetherlands,
and nine cases from Germany. All cases were genetically char-
acterized for the presence of germline mutations in the VHL,
RET,NF-1,MAX, SDHAF2, SDHA, SDHB, SDHC, and SDHD
on either blood or tissue samples, and for the presence of somatic
mutations in VHL, RET, EPAS1, and MAX on tumor tissue
samples when screening for germline mutations was negative.
Genetic screening was performed independently in the enrolling
centers as clinical routine work, and methodological conditions
are available from the authors upon request.
Among this series, 107 cases, 76 PCCs, and 31 PGLs, har-
bored somatic or germline mutations in one of the susceptibility
genes discussed above (Supplemental Figure 1). The residual 140
PCCs and 24 PGLs lacked germline or somatic mutations in the
main PCCandPGL susceptibility genes.All except three patients
were diagnosed with a single tumor and none had family history
of thedisease. InstitutionalReviewBoardapprovalwasobtained
for the study by each of the centers, and informed consent was
obtained from all patients.
Clinical variables collected for this study included sex, age,
number of PCC/PGLs, tumor location, tumor size, necrosis, cap-
sular and vascular invasion, mitotic index, as well as presence of
metastatic disease. Malignancy was defined as the presence of
metastases where chromaffin cells are normally absent. These
clinical variables were collected electronically into preformatted
forms provided to all contributors and statistically analyzed in a
single center.
DNA extraction and RAS gene mutations
DNA was extracted from either fresh frozen or formalin-
fixed, paraffin-embedded specimens, using standard protocols.
Sections of each sample were evaluated by a pathologist and
contained at least 80% of tumor cells. All cases, including the
series of tumors without known mutations (no. 164) and those
with already-known genemutations (no. 107) were screened for
hotspotmutations inH-,N-, andK-RAS genes (exons 2 and3 for
N- and K- and exons 2, 3, and 4 for H-RAS) in three centers
(Madrid,Rotterdam, andTurin). Either Sanger sequencing (Ma-
drid and Rotterdam) or pyrosequencing (Turin) methods were
employed. For direct sequencing, amplified DNA was purified
anddirectly sequencedusinganautomatic sequencerABIPRISM
TM 3700 (Applied Biosystems). Pyrosequencing method was
applied as previously described (17). PCR and sequencing prim-
ers were designed using the PSQ Assay Design Software version
1.0.6 (Biotage AB), and sequencing was performed using a Py-
roGold reagentKit (BiotageAB) and analyzed using PSQ-96MA
2.0.2 software (Biotage AB). Primer sequences not already pub-
lished for both direct sequencing and pyrosequencing are avail-
able as Supplemental Table 1.
Statistical analysis
The correlation between RAS mutations and known clinical
pathological parameters was assessed by 2 and Student t tests;
P .05was set as the level of significance. Statistical analysiswas
performed using GraphPad Prism 4 and SPSS software (IBM).
Results
H-RAS mutations are restricted to sporadic PCCs
H-RAS mutations were detected in 14 cases, all PCCs
without germline or somatic mutations in any of the
knownPCC/PGL susceptibility genes. In contrast, none of
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the familial PCCs (n 76) nor any of PGLs (n 55) tested
positive for H-RAS mutations in the present series.
Thereby, the overall prevalence of H-RAS mutations in
this cohort of PCCs/PGLs was 5% (14/271) with 8% (14/
164) considering cases without known mutations only,
and 10% (14/140) considering PCCs without knownmu-
tations, only. The most common mutation was H-RAS
p.Q61R (12 cases), the remaining two being one H-RAS
p.Q61KandoneH-RASp.G13Rmutation.Nomutations
were found inH-RAS exon 4. The corresponding normal
tissue of the 14 mutated cases tested in parallel for exons
2 and 3 was negative, thus showing the somatic nature of
H-RAS mutations. The prevalence of mutations did not
significantly differ among centers performing mutation
analysis (9.7, 9.1, and 12% in Madrid, Turin, and Rot-
terdam, respectively, P  .92), thus indicating that both
methods employed have a similar sensitivity. N- and K-
RAS sequencing did not reveal any disease-causing
mutation.
H-RAS mutations in PCCs lack significant clinical or
pathological correlations.
Themajor pathological and clinical features ofH-RAS-
mutated PCC were compared with cases without known
mutations (Table 1). H-RAS-mutated PCCs showed het-
erogeneousmorphology,without specific growthpatterns
or cytological features (Figure 1). A female predominance
wasobserved inour series, and themedian agewas slightly
older than PCCcaseswithout knownmutations, although
without reaching statistical significance. With regard to
morphological parameters potentially associated with
clinical aggressiveness (such as size, multicentricity, pres-
ence of vascular and/or capsular invasion and necrosis),
H-RAS-mutated PCCs were not significantly different
from PCCs without known mutations. Although most
cases were clinically benign, one patient died after local
recurrence, another patient presented vascular invasion,
and another a single necrotic focus, thus not excluding
that, as for sporadic PCCs in general, a small proportion
ofH-RAS-mutated PCCsmight have
a potential malignant biological
behavior.
Discussion
SomaticH-RASgenemutationshave
been reported recently in PCCs and
PGLs, thus increasing the number of
genetic alterations associated with
these tumors. In the article by Crona
et al (13), 82 cases were analyzed,
including 25 positive for known
PCC/PGL susceptibility genes. Four
mutated cases were described, one
PCCs and one PGL, all sporadic and
devoid of mutations in other suscep-
tibility genes. The patients were all
males with a benign clinical course.
This prompted us to explore the
prevalence ofRASmutations in a co-
hort of 271 PCCs and PGLs from the
Figure 1. Heterogeneous morphological features of H-RAS-mutated PCCs. H-RAS-mutated PCC
showed heterogeneous cytological and architectural features, with small (A) to large (B) nests of
cells having either scant clear/eosinophilic (A) or abundant basophilic (B) cytoplasm.
Representative pyrograms showing a mutation in H-RAS (C) as compared with wild-type (D)
normal adrenal tissue: H-RAS p.Q61R mutation, c.182AG substitution, is demonstrated in (C)
by a lower peak corresponding to (A) and a higher peak corresponding to G in the sequence
(arrow) as compared with the wild type sequence in (D).
Table 1. Main Clinical and Pathological Features of
H-RAS-mutated and Wild-Type PCC
Parameter PCC H-RAS
PCC Without
Known
Mutations P Value
N 14 126
M/F 5/9 61/65 .27
Median age, y [range] 59 [38–79] 51 [14–81] .08
Median Size, mm
[range]
50 [17–90] 53 [11–200] .83
Presence of
multicentric
disease/total
0/14 3/122 1.0
Presence of VI/total 1/13 13/115 1.0
Presence of CI/total 0/14 11/112 .61
Presence of necrosis/
total
1/14 19/112 .46
Clinically malignant
disease/total
1/13a 5/119 .47
Abbreviations: M, male; F, female; VI, vascular invasion; CI, capsular
invasion.
a One patient died of unknown causes and was considered not
informative.
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ENS@Tregistry and to compare the genotypewith clinical
and pathological characteristics of potential clinical inter-
est. In our series, theH-RAS genewas found to bemutated
exclusively among theRAS genes in 5%of PCC/PGLs. All
mutated cases were PCCs, clinically sporadic andwithout
mutations in other known PCC/PGL susceptibility genes.
Thus,wecould confirmthe sporadic and thewild-type (for
other genes) characteristics of H-RAS-mutated tumors,
but not the presence ofmutations in PGL, because none of
the 55 PGLs tested (24 without known mutations and 31
mutated in other genes) was positive. Therefore, the prev-
alence of H-RAS mutations in sporadic PCC without
knownmutations inother genes shouldapproximate10%
of cases, whereas it seems to be extremely rare (0% in our
series) in PGL with the same characteristics.
Clinical and pathological correlations were limited by
the small number of H-RAS-mutated tumors. However,
our series showed, differently from the article by Crona et
al, a female predominance and a higher median age (49.5
y in the article by Crona et al, 59 y in our series). These
features, however, were not significantly different from
sporadic PCCs without H-RAS mutation. Moreover, as
described in the fourH-RASmutant cases reported so far,
most the cases in our series did not show an aggressive
clinical course. However, one patient died with local re-
currence after 9 y; in addition, in twocases,morphological
features suspected of potentially malignant behavior
(presence of vascular invasion or necrosis) were recorded;
a third case had moderate mitotic (three mitoses in 10
high-power fields) index. Moreover, none of the param-
eters considered was significantly different in the group of
H-RAS-mutated as compared with wild-type PCCs.
Therefore, although the occurrence of metastases at the
time of diagnosis or during follow-up has not been de-
scribed in these tumors, a long-term follow-up is required,
especially for patients with clinical predictors of malig-
nancy. Interestingly, the single case associated with local
recurrence in our series had a large size, in agreement with
previous data in the literature (18).
In contrast, ourdata confirm thatH-RASmutations are
among the driver pathogenetic alterations in sporadic
PCC. It is worth noticing that, among the different types
of cancers harboring somatic RAS mutations, a relevant
prevalence of H-RAS mutations has been documented in
sporadic medullary carcinoma (19), although without a
specific association with prognosis. Therefore, both PCC
and medullary thyroid carcinoma share a similar genetic
background but, different from medullary carcinoma,
germlineor somaticRETmutations inPCCarenotusually
associated with aggressive behavior (20, 21).
All the above observations suggest that H-RAS-muta-
tion testing is of potential impact in sporadic PCC and
must be validated as a clinicallymeaningful routine test. In
fact, although not significantly associated with a specific
clinical behavior, the value of H-RAS genotyping to pre-
dict therapeutic responsiveness cannot be excluded until
its capability to guide systemic therapeutic approaches
will be tested in metastatic H-RAS positive PCCs.
In conclusion, H-RAS mutations are causative for the
10% of PCCs without mutations in other known PCC-
related genes and should be considered as part of routine
genetic screeningwhen tumor tissue is available tovalidate
its diagnostic, prognostic, or predictive role as amolecular
biomarker.
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